Dr. Daud on Challenges Facing the Treatment Landscape for Melanoma

Adil Daud, MD
Published: Thursday, Oct 19, 2017



Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

One question that remains is which treatment patients should receive. According to Daud, there are advantages and disadvantages to each treatment option.

For most treatments, there will be at most 20% complete responses, but more research is needed to be done to increase that percentage. Potentially combining therapies could increase the response rates for patients, states Daud.

<<< View more from the World Congress of Melanoma


Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

One question that remains is which treatment patients should receive. According to Daud, there are advantages and disadvantages to each treatment option.

For most treatments, there will be at most 20% complete responses, but more research is needed to be done to increase that percentage. Potentially combining therapies could increase the response rates for patients, states Daud.

<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x